The European Commission’s Pharmaceutical Sector Inquiry raised significant concerns regarding so-called “reverse payment” patent settlement agreements. In this article, CRA describes the types of information or economic evidence that might facilitate evaluation of the competitive aspects of these settlements. To read the article, click here:
CRA named Top 3 Litigation Dispute Advisory Services Consultant in The National Law Journal
CRA’s Chicago Practice is proud to have been ranked as one of the Top 3 Litigation Dispute Advisory Services Consultancies in The National Law Journal’s “Best...